Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

Olink Holding AB (publ)

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
 
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
 
For more information visit www.olink.com

Olink Proteomics

Touchdown in London! We're eager to discuss proteomics with you at the Festival of Genomics!

Swing by Booth #109 to discover how integrating genomics and proteomics helps reveal novel drug targets and new insights into disease pathways. Plus, don't miss your chance to see our Signature Q100 instrument in action!

We're looking forward to sharing ideas and learning together. Come and join the conversation!

#Olink #Proteomics #FOG2024



Will in-depth proteome profiling using self-sampled blood be the next step in monitoring individual health status in the era of precision medicine? Let’s hear the most recent progress in this topic from Professor Jochen M Schwenk (Royal Institute of Technology, Sweden) and discuss the challenges together in the session on Disease Proteomics at 29th Annual Lorne Proteomics Symposium on Feb 2, 2024, at Lorne, Australia!  

Check out the full symposium program at
https://bit.ly/3RMSubI 
#Proteomics #LorneProteomicsSymposium #Australia

We are thrilled to kick off the new year of events and connecting in person with you as our AMER team gears up for their first event of 2024 – PMWC (Precision Medicine World Conference)!
 
From our start, our mission has been to achieve the goal of precision medicine and individualized healthcare through the advancement of protein biomarker discovery and analysis. This future can only be realized with the collaboration of the scientific community so we are thrilled to connect with you at PMWC 2024 and the many events our teams will be attending. Stay tuned for updates as our team engages in insightful discussions and seeks to contribute to the future of healthcare.
 
Here's to a year filled with innovation, learning, and impactful connections! Let's make 2024 a year to remember! 🎉 

#PMWC2024 #precisionmedicine #olink

Extracting new insights from your genomics data? Discovering novel drug targets?
 
We're excited to share the power of proteomics with you at the Festival of Genomics & Biodata in London on Jan 24-25, 2024!
 
From biobank studies to disease-focused research, proteomics can empower your genomics projects and help you understand real-time human biology and overcome drug development challenges.
 
Come meet us at Booth #109 to discover how proteomics can complement your genomics studies and see our Signature Q100 instrument in action.
 
#Olink #Proteomics #FOG2024

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.12 -	0.13 5.77%	0.18 38.41%	0.29 66.88%	0.28 3.92%
cash conversion cycle	431.16 -	541.56 25.61%	378.65 30.08%	465.37 22.90%	387.29 16.78%
cash per share	0.05 -	0.08 58.03%	1.19 1,353.98%	0.63 46.95%	0.98 54.56%
company equity multiplier	1.68 -	1.42 15.74%	1.13 20.04%	1.16 2.20%	1.20 3.30%
days of inventory outstanding	333.32 -	435.47 30.65%	287.33 34.02%	356.12 23.94%	341.37 4.14%
days of payables outstanding	57.65 -	139.22 141.50%	86.06 38.18%	55.42 35.61%	96.39 73.93%
days of sales outstanding	155.49 -	245.31 57.77%	177.38 27.69%	164.67 7.17%	142.30 13.58%
dividend yield
ebit per revenue	-0.26 -	-0.11 56.01%	-0.47 317.88%	-0.22 53.46%	-0.29 34.32%
ebt per ebit	1.74 -	1.19 31.33%	1.04 12.65%	0.50 51.70%	0.80 59.00%
effective tax rate	0.04 -	0.07 87.54%	0.18 167.18%	0.17 5.90%	0.21 25.45%
enterprise value multiple	-1.57K -	598.61 138.17%	-55.51 109.27%	-254.52 358.54%	-97.86 61.55%
fixed asset turnover	5.54 -	5.17 6.73%	4.42 14.45%	5.61 26.75%	2.98 46.85%
free cash flow per share	-0.18 -	-0.17 6.56%	-0.69 304.58%	-0.32 52.97%	-0.41 27.58%
gross profit margin	0.69 -	0.68 1.54%	0.61 9.49%	0.68 10.25%	0.58 13.88%
interest coverage	-1.62 -	-0.92 43.23%	-21.80 2,276.69%	-57.63 164.33%	-58.21 1.00%
inventory turnover	1.10 -	0.84 23.46%	1.27 51.56%	1.02 19.32%	1.07 4.32%
long term debt to capitalization	0.21 -	0.18 18.04%	0.01 93.59%	0.02 55.28%	0.04 147.33%
net income per ebt	0.96 -	0.93 3.19%	0.82 11.81%	0.83 1.26%	0.79 5.06%
net profit margin	-0.43 -	-0.13 70.76%	-0.40 221.92%	-0.09 77.24%	-0.19 102.76%
operating cash flow per share	-0.18 -	-0.06 63.67%	-0.54 742.66%	-0.25 53.29%	-0.24 4.11%
operating cycle	488.81 -	680.78 39.27%	464.71 31.74%	520.79 12.07%	483.67 7.13%
operating profit margin	-0.26 -	-0.11 56.01%	-0.47 317.88%	-0.22 53.46%	-0.29 34.32%
payables turnover	6.33 -	2.62 58.59%	4.24 61.77%	6.59 55.30%	3.79 42.51%
pretax profit margin	-0.44 -	-0.13 69.79%	-0.49 265.03%	-0.11 77.52%	-0.24 113.57%
price fair value	20.80 -	12.71 38.92%	3.80 70.11%	7.35 93.65%	6.20 15.65%
receivables turnover	2.35 -	1.49 36.62%	2.06 38.30%	2.22 7.72%	2.57 15.72%
return on assets	-0.05 -	-0.02 69.07%	-0.07 345.57%	-0.03 62.01%	-0.05 94.82%
return on capital employed	-0.04 -	-0.02 57.94%	-0.09 473.23%	-0.07 20.88%	-0.09 31.38%
return on equity	-0.09 -	-0.02 73.94%	-0.08 256.28%	-0.03 61.18%	-0.06 101.25%
total debt to capitalization	0.33 -	0.18 44.86%	0.02 90.42%	0.02 29.74%	0.05 125.28%

COM:OLINK

Olink Holding AB

Last Close

26.00

09/07 20:00

Market Cap

3.24B

Beta: -

Volume Today

1.89M

Avg: -

Preview